<DOC>
	<DOCNO>NCT03091426</DOCNO>
	<brief_summary>This study randomize , double-blind , placebo-controlled design ass efficacy , pharmacodynamics safety/tolerability omiganan patient mild moderate atopic dermatitis apply BID atopic dermatitis lesion .</brief_summary>
	<brief_title>Pharmacodynamics Omiganan BID Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female subject mild moderate AD ( IGA 2 3 ) 18 65 year age , inclusive . The health status verify absence evidence clinical significant active uncontrolled chronic disease AD follow detailed medical history , complete physical examination include vital sign , 12lead ECG , hematology , blood chemistry , virology urinalysis ; Confirmed AD diagnosis ; Symptoms present least 1 year ; EASI 7.1 50.0 , inclusive screening ; 220 % body surface area ( BSA ) affect screen ; Body mass index ( BMI ) 18 35 kg/m2 , inclusive , minimum weight 50 kg ; Able participate willing give write informed consent comply study restriction ; Subjects partner childbearing potential must use effective contraception , duration study 3 month last dose . Any current / recurrent clinical significant skin condition AD ; Pregnant , positive pregnancy test , intend become pregnant , breastfeed ; Ongoing use prohibit atopic dermatitis treatment . Requires washout period prior baseline ( first dose study drug ) ; Use topical medication ( prescription overthecounter [ OTC ] ) within 14 day study drug administration , less 5 halflives ( whichever longer ) local treatment area ; Tanning due sunbathing , excessive sun exposure tan booth within 3 week enrollment ; Known hypersensitivity compound excipients compound know hypersensitivity one different emollient ; Participation investigational drug device study within 3 month prior screen 4 time year ; Loss donation blood 500 mL within three month ( male ) four month ( female ) prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>